GlobeNewswire: Arch Therapeutics, Inc. Contains the last 10 of 200 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T10:34:28ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/11/09/2777143/0/en/Arch-Therapeutics-Provides-Year-End-Operational-Update.html?f=22&fvtc=4&fvtv=37924Arch Therapeutics Provides Year End Operational Update2023-11-09T11:50:00Z<![CDATA[Continued Strong Trends in Orders and Paid Claims Continued Strong Trends in Orders and Paid Claims]]>https://www.globenewswire.com/news-release/2023/11/02/2772072/0/en/Arch-Therapeutics-to-Present-AC5-Advanced-Wound-System-at-the-2023-Symposium-on-Advanced-Wound-Care-Fall-Meeting-SAWC-Fall.html?f=22&fvtc=4&fvtv=37924Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)2023-11-02T10:50:00Z<![CDATA[AC5® Advanced Wound System to be Featured in the Hands-On Skills Lab for Clinicians and a Clinical Case Poster Demonstrating Utility in Treatment of Venous Leg Ulcers AC5® Advanced Wound System to be Featured in the Hands-On Skills Lab for Clinicians and a Clinical Case Poster Demonstrating Utility in Treatment of Venous Leg Ulcers]]>https://www.globenewswire.com/news-release/2023/09/13/2742305/0/en/Arch-Therapeutics-Provides-AC5-Commercialization-Update.html?f=22&fvtc=4&fvtv=37924Arch Therapeutics Provides AC5® Commercialization Update2023-09-13T10:45:00Z<![CDATA[Orders and Paid Claims Increasing Since Rollout of Reimbursement Code Orders and Paid Claims Increasing Since Rollout of Reimbursement Code]]>https://www.globenewswire.com/news-release/2023/09/07/2739833/0/en/Arch-Therapeutics-Completes-Financing-as-Bridge-to-Uplisting.html?f=22&fvtc=4&fvtv=37924Arch Therapeutics Completes Financing as Bridge to Uplisting2023-09-07T23:14:50Z<![CDATA[Common Stock Listing on National Exchange is Next Planned Significant Milestone Common Stock Listing on National Exchange is Next Planned Significant Milestone]]>https://www.globenewswire.com/news-release/2023/04/25/2653680/0/en/Arch-Therapeutics-to-Present-AC5-Advanced-Wound-System-at-2023-Symposium-on-Advanced-Wound-Care-SAWC.html?f=22&fvtc=4&fvtv=37924Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)2023-04-25T10:50:00Z<![CDATA[SAWC Spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated AC5 HCPCS reimbursement code SAWC Spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated AC5 HCPCS reimbursement code]]>https://www.globenewswire.com/news-release/2023/04/05/2641507/0/en/Dedicated-HCPCS-Billing-Code-for-Arch-Therapeutics-AC5-Advanced-Wound-System-Now-In-Effect.html?f=22&fvtc=4&fvtv=37924Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In Effect2023-04-05T10:50:00Z<![CDATA[New code is expected to advance commercialization efforts in doctors’ offices and other outpatient settings New code is expected to advance commercialization efforts in doctors’ offices and other outpatient settings]]>https://www.globenewswire.com/news-release/2023/03/09/2623993/0/en/Arch-Therapeutics-AC5-Advanced-Wound-System-Receives-Dedicated-HCPCS-Billing-Code-from-The-Centers-for-Medicare-Medicaid-Services.html?f=22&fvtc=4&fvtv=37924Arch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services2023-03-09T12:50:00Z<![CDATA[The new code represents a key milestone for the commercialization of AC5® Advanced Wound System in doctors’ offices and other outpatient settings The new code represents a key milestone for the commercialization of AC5® Advanced Wound System in doctors’ offices and other outpatient settings]]>https://www.globenewswire.com/news-release/2023/03/07/2621948/0/en/Arch-Therapeutics-Announces-Addition-of-Contract-Sales-Force-to-Advance-Commercialization-of-AC5-Advanced-Wound-System-in-Government-Facilities.html?f=22&fvtc=4&fvtv=37924Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities2023-03-07T12:50:00Z<![CDATA[Dedicated representation in selected geographic locations to support new and recurring sales in government facilities Dedicated representation in selected geographic locations to support new and recurring sales in government facilities]]>https://www.globenewswire.com/news-release/2023/01/18/2590825/0/en/Arch-Therapeutics-Announces-Formation-of-Medical-Advisory-Board-to-Advance-Commercialization-of-AC5-Advanced-Wound-System.html?f=22&fvtc=4&fvtv=37924Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System2023-01-18T12:35:00Z<![CDATA[Wound care professionals across multiple specialties to support strategic alignment of patient, payor, and provider goals Wound care professionals across multiple specialties to support strategic alignment of patient, payor, and provider goals]]>https://www.globenewswire.com/news-release/2023/01/17/2590502/0/en/Arch-Announces-One-for-Two-Hundred-Reverse-Stock-Split-in-Connection-with-Application-for-Uplisting-to-a-National-Exchange.html?f=22&fvtc=4&fvtv=37924Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange2023-01-17T21:05:00Z<![CDATA[FRAMINGHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it will effect a 1-for-200 reverse stock split of its outstanding and authorized common stock, effective at 5:00 p.m. (EST) on January 17, 2023. Arch’s common stock will continue to trade on the OTCQB under the symbol “ARTHD” and under a new CUSIP number, 03939W 208. Arch’s common stock will begin trading on a reverse stock split-adjusted basis on the OTCQB when the market opens on January 18, 2023.]]>